Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Cytori and Lorem Announce China Approval of Regenerative Medicine Device

publication date: Apr 6, 2015
Cytori Therapeutics of San Diego, together with its China-Asia licensee, Lorem Vascular, received CFDA regulatory clearance to market the Cytori Celution® System, a device that processes stem cells from adipose tissue. The companies did not specify an indication for the device, though it has been in trials elsewhere as a treatment for heart failure, scleroderma and osteoarthritis along with aesthetic uses. In 2013, Lorem signed a $531 million, 30-year deal to in-license rights for the system in China, Hong Kong, Malaysia, Singapore and Australia. More details....

Stock Symbol: (NSDQ: CYTX)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital